| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:NSC 107512
CAS:22242-89-3
Purity:98% Package:100 mg；25 mg；50 mg
|
| Company Name: |
Shanghai?Medlife?Pharm-Tech?Co.,?Ltd
|
| Tel: |
021-59167510 18117107507 |
| Email: |
vip@med-life.cn |
| Products Intro: |
Product Name:NSC 107512
CAS:22242-89-3
Purity:>=99% Package:50mg;100mg;25mg
|
|
| | 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxamidoxime, 4-amino-7-.beta.-D-ribo furanosyl- Basic information |
| | 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxamidoxime, 4-amino-7-.beta.-D-ribo furanosyl- Chemical Properties |
| Boiling point | 746.5±70.0 °C(Predicted) | | density | 2.10±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C, protect from light, stored under nitrogen | | solubility | DMSO : 170 mg/mL (524.22 mM; Need ultrasonic) | | pka | 6.16±0.69(Predicted) |
| | 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxamidoxime, 4-amino-7-.beta.-D-ribo furanosyl- Usage And Synthesis |
| Biological Activity | NSC 107512 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9). NSC 107512 is a class of sangivamycin-like molecules (SLM). NSC 107512 inhibits growth and induces apoptosis of multiple myeloma tumors[1]. | | References | [1]. Dolloff NG, et al. Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9. Mol Cancer Ther. 2012;11(11):2321-2330. |
| | 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxamidoxime, 4-amino-7-.beta.-D-ribo furanosyl- Preparation Products And Raw materials |
|